Sunday, 11 July 2010 at 11:35, Reuters, Honolulu
Avid Radiopharmaceuticals has taken an unconventional approach in developing its experimental imaging agent to find brain plaques associated with Alzheimer's disease. The privately held company is making it available to just about anybody who needs it for research, including the US National Institute on Aging's Alzheimer's Disease Neuroimaging Initiative, or ADNI, a five-year, $60 million study aimed at identifying early signs of Alzheimer's disease.
"From the very beginning, it has been our idea to make the compound available to whoever wants it. We never say no," Dr. Daniel Skovronsky, chief executive of Philadelphia-based Avid Radiopharmaceuticals, said in an interview on Saturday at the Alzheimer's Imaging Consortium in Honolulu. The meeting is taking place ahead of the Alzheimer's Association scientific meeting, where Avid's late-stage clinical study results will be presented on Sunday.
Your comments